Clinical aspects of radiation nephropathy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 3, 2004, Pages 359-362

  Breitz, Hazel ^a  

^a Poniard Pharmaceuticals Inc   (United States)

Author keywords

Radiation nephropathy; Radionuclide therapy; Thrombo microangiopathy

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; RADIOISOTOPE;

ANEMIA; BONE MARROW TOXICITY; CANCER RADIOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DRUG TOLERANCE; EDEMA; FEVER; HEMATURIA; HEMOLYTIC UREMIC SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERTENSION; KIDNEY DISEASE; MICROANGIOPATHY; NEPHROTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; RADIATION EXPOSURE; RADIATION INJURY; RADIATION NEPHROPATHY; RADIOISOTOPE THERAPY; REVIEW; URINARY EXCRETION;

ANIMALS; BONE MARROW TRANSPLANTATION; HUMANS; KIDNEY; KIDNEY DISEASES; RADIOISOTOPES;

EID: 3142748327     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/1084978041425106     Document Type: Review

References (18)

1. Baerman G, Linser P. Review of localized and general effects of radiation. Munch Med Wschr 1904;7:996.
2. Luxton RW, Kunkler PB. Radiation nephritis. Acta Radiol 1962;2:169.
3. Krochak R, Baker DG. Clinical manifestations and pathophysiological mechanisms. Urology 1986;27:389.
4. Robbins M, Stephens L, Johnston D, et al. A morphometric analysis of glomerular and tubular alterations following fast neutron irradiation of the pig and monkey kidney. Int J Rad Biol Phys 1998;41:1149.
5. Cohen E. Radiation nephropathy after bone marrow transplantation. Kidney Int 2000;58:903.
6. Iacopino P, Pucci G, Arcese W, et al. (GITMO). Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Bone Marrow Transpl 1999;24:47.
7. Petit AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transpl 1994;14:495.
8. Holler E, Kolb H, Hiller E, et al. Microangiopathy in patients on cyclosporin prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 1989;73:2018.
9. Bergstein J, Andreoli S, Provisor A, et al. Radiation nephritis following total-body irradiation and cyclophosphamide in preparation for bone marrow transplantation. Transpl 1986;41:63.
10. Chappell M, Keeling D, Prentice H, et al. Hemolytic uremic syndrome after bone marrow transplantation: an adverse effect of total body irradiation. Bone Marrow Transpl 1988;3:339.
11. Gonzalez-Vicente M, Diaz MA, Madero L. An uncommon case of late thrombotic thrombocytopenic purpura (42 months) after autologous PBSC transplantation in a child. Bone Marrow Transpl 1999;23:725.
12. Wasserman N, Martin H, Elsner S, et al. Microangiopathic hemolytic anemia and renal impairment following autologous bone marrow transplantation: A case of hemolytic uremic syndrome. Bone Marrow Transpl 1984;114:849.
13. Cremenosi M, Ferrari M, Chinol M, et al. Dosimetry in radionuclide therapies with 90Y-conjugates: The IEO experience. Q J Nucl Med 2000;44:325.
14. Moll S, Nickeleit V, Mueller-Brand J, et al. A new cause of thrombotic microangiopsathy: yttrium 90-DOTA-TOC internal radiotherapy. Am J Kidney Dis 2001;37:847.
15. Knox S, Goris M, Tempero M, et al. Phase II trial of yttruim-90-DOTA- biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 1999;6:406.
16. 166Ho-DOTMP plus melphalan followed by peripheral blood stem-cell transplantation in patients with multiple myeloma: Results of two phase I-II trials. Blood 2003; 102:2684.
17. Bouchet LG, Bolch WE, Blanco HP, et al. MIRD pamphlet no. 19: Absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med 2003;44:1113.
18. Dale RG. Dose-rate effects in targeted radiotherapy. Phys Med Biol 1996;41:1871.